secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001213900-23-017841
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive raises up to $130M in private placement led by Vivo Capital for Renazorb launch
--------------------------------------------------------------------------------

- $30M upfront from Series A-1 Convertible Preferred Stock; up to $100M additional via milestone-linked warrants.
- Tranche A warrants ($25M) exercisable upon FDA approval of Renazorb; Tranche B ($25M) upon TDAPA approval; Tranche C ($50M) after four quarters of commercial sales.
- Gaurav Aggarwal, MD (Vivo Capital) appointed to Board of Directors effective at closing.
- Company to adopt dividend policy paying at least 75% of annual net cash flow from operations to all stockholders post-approval and commercial sales.
- Proceeds to support NDA submission for Renazorb (hyperphosphatemia) and potential U.S. commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/ea174702-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-017841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer